Optimal diabetes management during medical weight loss for cardiovascular risk reduction

Expert Review of Cardiovascular Therapy

Volumn 3, Issue 4, 2005, Pages 761-775

  Nori Janosz, Katherine E ^a   Miller, Wendy M ^a   Odom, Jacqueline ^a   Lillystone, Martin ^a   Yanez, Jose ^a   McCullough, Peter A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Behavior therapy; Cardiovascular risk; Cardiovascular risk factors; Diabetes; Diabetes treatment; Diet; Exercise; Meal replacement; Medical nutrition therapy; Obesity; Portion control; Weight control; Weight program

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACETYLSALICYLIC ACID; ANTIOBESITY AGENT; APD 356; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; CANNABINOID RECEPTOR ANTAGONIST; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; CILIARY NEUROTROPHIC FACTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV; FIBRIC ACID DERIVATIVE; GI 181771; HUMAN GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LEPTIN DERIVATIVE; MELANOCORTIN 4 RECEPTOR AGONIST; METFORMIN; PEGOAXOKINE; PEPTIDE YY; RECOMBINANT CILIARY NEUROTROPHIC FACTOR; RIMONABANT; SEROTONIN 2C AGONIST; SIBUTRAMINE; SIMVASTATIN; SULFONYLUREA; TETRAHYDROLIPSTATIN; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGE DISTRIBUTION; BEHAVIOR THERAPY; BODY WEIGHT DISORDER; CALORIC RESTRICTION; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL TRIAL; DIABETIC ANGIOPATHY; DIET THERAPY; DRUG MECHANISM; FEEDING BEHAVIOR; HEALTH CARE COST; HUMAN; KINESIOTHERAPY; LONG TERM CARE; LOW FAT DIET; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL SUPPORT; OBESITY; PREVALENCE; REVIEW; RISK FACTOR; RISK REDUCTION; SURGICAL TECHNIQUE; UNITED STATES; WEIGHT GAIN; WEIGHT REDUCTION; WESTERN HEMISPHERE;

CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DIET; HUMANS; OBESITY; RISK FACTORS; WEIGHT LOSS;

EID: 23144450218     PISSN: 14779072     EISSN: None     Source Type: Journal    
DOI: 10.1586/14779072.3.4.761     Document Type: Review

References (96)

1. Flegal KM, Carrol MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288(14), 1723-1727 (2002).
2. Lloyd-Jones DM, Liu K, Colangelo LA, Yan LL, Klein L. Consistently stable body mass index and changes in risk factors associated with the metabolic syndrome. Circulation (2004) (Abstract 3567).
3. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes estimates for the year 2000 and projections for 2030. Diabetes Care 27, 1047-1053 (2004).
4. Maggio C, Pi-Sunyer X. Obesity and Type 2 diabetes. Endocrinol. Metab. Clin. N. Am. 32, 805-822 (2003).
5. Cho E, Manson J, Stampfer M et al. A prospective study of obesity and risk of coronary heart disease among diabetic women. Diabetes Care 25, 1142-1148 (2002).
6. Must A, Spadano J, Coakly EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 282, 1523-1529 (1999).
7. DECODE Study Group; on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch. Intern. Med. 161, 397-405 (2001).
8. Grundy SM, Howard, B, Smith S et al. Prevention Conference IV: Diabetes and cardiovascular disease. Circulation 105, 2231-2239 (2002).
9. Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in Type 2 diabetes: review with meta-analysis of clinical studies. J. Am. Coll. Nutr. 22(5), 331-339 (2003).
10. Pi-Sunyer FX. Comorbidities of overweight and obesity: current evidence and research issues. Med. Sci. Sports Exerc. 31, S602-S608 (1999).
11. Pi-Sunyer FX. Medical hazards of obesity. Ann. Intern. Med. 119, 655-660 (1993).
12. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch. Intern. Med. 162, 1867-1872 (2002).
13. Krauss RM, Winston M, Fletcher RN, Grundy SM. Obesity: impact of cardiovascular disease. Circulation 98, 1472-1476 (1998).
14. Franz MJ, Bantle JP, Beebe CA et al. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care 26(Suppl.), S51-S61 (2003).
15. Dixon JB, O'Brien PE. Health outcomes of severely obese type 2 diabetic subjects 1 year after laproscopic adjustable gastric banding. Diabetes Care 25, 358-363 (2002).
16. Frank A. Futility and avoidance. Medical professionals in the treatment of obesity. JAMA 269, 2132-2133 (1993).
17. National Institute of Health/National Heart, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Obes. Res. 651S-209S. (1998).
18. Plodkowski R, St. Jeor S. Medical nutrition therapy for the treatment of obesity. Endocrinol. Metab. Clin. N. Am. 32, 935-965 (2003).
19. ADA Standards of Medical Care in Diabetes - Position Statement. Diabetes Care 28(Suppl. 1) S4-S36 (2005).
20. Klein S, Sheard N, Pi-Sunyer X et al. Weight management through lifestyle modification for the prevention and management of Type 2 diabetes: rational and strategies. A statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Am. J. Clin. Nutr. 80, 257-263 (2004).
21. Krauss RM, Eckel RH, Howard B et al. AHA dietary guidelines: revison 2000. A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation 102, 2284-2299 (2000).
22. National Cholesterol Education Program. Executive summary of the third report of the National Cholesterol Education Program expert panel on selection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285, 2486-2497 (2001).
23. National Institutes of Health, National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. NIH, MD, USA (1998).
24. Tsai A, Wadden T. Systematic review: an evaluation of major commercial weight loss programs in the United States. Ann. Intern. Med. 142, 55-66 (2004).
25. Wadden TA, Forester GD, Letizia KA. One-year behavioral treatment of moderate and severe caloric restriction and the effects of weight maintenance therapy. J. Consult. Clin. Psychol. 62, 165-171 (1994).
26. Yang H, Petersen GM, Roth M-P et al. Risk factors for gallstone formation during rapid loss of weight. Dig. Dis. Sci. 37, 912-918 (1995).
27. Saris WH. Very-low-calorie diets and sustained weight loss. Obes Res. 9(Suppl. 4), 295S-301S (2001).
28. Anderson JW, Kong EC, Fredric ARC, Wood CL. Long-term weight-loss maintenance: a meta-analysis of US studies. Am. J. Clin. Nutr. 74, 579-584 (2001).
29. Anderson JW, Luan J, Hoie LH. Structured weight-loss programs: meta-analysis of weight loss at 24 weeks and assessment of effects of intervention intensity. Adv. Ther. 21, 61-75 (2004).
30. Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am. J. Cardiol. 83, 25F-29F (1999)
31. Koutsari C, Hardman AE. Exercise prevents the augmentation of postprandial lipaemia attributable to low-fat high-carbohydrate diet. Br. J. Nutr. 86(2), 197-206 (2001).
32. Seshadri P, Iqbal N, Stern L, Williams M et al. A randomized study comparing the effects of a low-carbohydrate diet and a conventional diet on lipoprotein subfractions and C-reactive protein levels in patients with severe obesity. Am. J. Med. 117, 498-405 (2004).
33. Meckling KA, O'Sullivan C, Saari D. Comparison of a low-carbohydrate diet on weight loss, body composition, and risk factors for diabetes and cardiovascular disease in free-living overweight men and women. J. Clin. Endocrinol. Metab. 89, 2717-2723 (2004).
34. Pitsovos C, Panagiotakos DB, Chrysohoou C et al. The effect of Mediterranean Diet on the risk of the development of acute coronary syndromes in hypercholesterolemic people: a case control study (CARDIO2000). Coron. Artery Dis. 13, 295-300 (2003).
35. Trichopoulou A, costacou T, Bamia C et al. Adherence to a Mediterranean Diet and survival in Greek Population. N. Engl. J. Med. 348, 2599-2608 (2003).
36. Heilbronn LK, Noakes M, Clifton PM. Effect of energy restriction, weight loss, and diet composition on plasma lipids and glucose in patients with Type 2 diabetes. Diabetes Care 22, 889-895 (1999).
37. Mattes RD. Ready-to-eat cereal used as a meat replacement promotes weight loss in humans. J. Am. Coll. Nutr. 21, 570-577 (2002).
38. Noakes M, Foster PR, Keogh JB, Clifton PM. Meal replacements are as effective as structured weight-loss for treating obesity in adults with features of metabolic syndrome. J. Nutr. 134, 1894-1899 (2004).
39. Heymsfield SB, van Mierlo CA, van der Knaap HC, Heo M, Frier HI. Weight management using a meal replacement strategy: meta and pooling analysis from six studies. Int. J. Obes. Relat. Metab. Disord. 27, 537-549 (2003).
40. Hannum SM, Carson L, Evans E et al. Use of portion-controlled entrees enhances weight loss in women. Obes. Res. 12, 538-546 (2004).
41. Ditschuneit HH, Frier HI, Flechtner-Mors M. Lipoprotein responses to weight loss maintenance in high-risk subjects. Eur. J. Clin. Nutr. 56, 264-270 (2002).
42. Li Z, Hong K, Saltsman P et al. Long-term efficacy of soy-based meal replacements vs. an individualized diet plan in obese Type II DM patients: relative effects on weight loss, metabolic parameters, and C-reactive protein. Eur. J. Clin. Nutr. 59(3), 411-418 (2005).
43. Vidal-Guevera ML, Samper M, Martinez-Silla G et al. Meal replacement as a dietary therapy for weight. Nutr. Hosp. 19, 202-208 (2004).
44. Harder H, Dinesen B, Astrup A. The effect of a rapid weight loss on lipid profile and glycemic control in obese Type 2 diabetic patients. Int. J. Obes. Relat. Metab. Disord. 28, 180-182 (2004).
45. Allison DB, Gadbury G, Schwartz LG et al. A novel soy-based meal replacement formula for weight loss among obese individuals: a randomized controlled clinical trial. Eur. J. Clin. Nutr. 57, 514-522 (2003).
46. Flechtner-Mors M, Ditschuneit HH, Johnson TD, Suchard MA, Adler G. Metabolic and weight loss effects of long-term dietary intervention in obese patients: four-year results. Obes. Res. 8, 399-402 (2000).
47. Wing RR. Food provision in dietary intervention studies. Am. J. Clin. Nutr. 66, 421-422 (1997).
48. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type 2 diabetic patients. Metabolism 39, 905-912 (1990).
49. Wing RR, Hill JO. Successful weight loss maintenance. Ann. Rev. Nutr. 21, 323-341 (2001).
50. Hadden DR, Blair ALT, Wilson EZ et al. Natural history of diabetes presenting age 40-69 years: a prospective study of influence of intensive dietary therapy. Q. J. Med. 59, 579-598 (1986).
51. Unsitupa M, Louheranta A, Lindstrom J et al. The Finnish Diabetes Prevention Study. Br. J. Nutr. 83(Suppl. 1), 137-142 (2000).
52. Knowler WC, Barrett-Conner E, Fowler SE et al. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393-403 (2002).
53. Li G, Yang W, Jiang Y et al. Effects of insulin secretion on the efficacy of interventions to retard development of Type 2 diabetes mellitus: the DA Qing IGT study and diabetes study. Diabetes Res. Clin. Pract. 58, 293-200 (2002).
54. Cox KL, Burke V, Morton AR, Beilin LJ, Puddey IB. Independent and additive effects of energy restriction and exercise on glucose and insulin concentrations in sedentary overweight men. Am. J. Clin. Nutr. 80, 308-316 (2004).
55. Eriksson K-F, Lindgarde F. Prevention of Type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. Diabetologia 34, 891-898 (1991).
56. Institutes of Health, National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. NIH, MD, USA (1998).
57. Thompson PD, Buchner D, Pina IL et al. Exercise and physical activity: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, an Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 107, 3109-3116 (2003).
58. NIH Consensus Development Panel on Physical Activity and Cardiovascular Health. Physical activity and cardiovascular health. JAMA 276, 241-246 (1996).
59. Visona C, George VA. Impact of dieting status and dietary restraint on post exercise energy intake in overweight women. Obes. Res. 10, 1251-1258 (2002)
60. Albright A, Franz M, Hornsby G et al. American College of Sports Medicine position stand. Exercise and Type 2 diabetes. Med. Sci. Sports Exerc. 32, 1345-1360 (2000).
61. Dela F, vonLinstow ME, Mikines KJ, Galbo H. Physical training may enhance β-cell function in Type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 287, E1024-E1031 (2004).
62. Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in Type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA 286, 1218-1227 (2001).
63. Troseid M, Lappegard KT, Claudi T et al. Exercise reduces plasma levels of the chemokines MCP-1 an IL-8 in subjects with the metabolic syndrome. Eur. Heart J. 25(4), 349-355 (2004).
64. Albu J, Raja-Khan N. The management of the obese diabetic patient. Prim. Care Clin. Office Pract. 30, 465-491 (2003).
65. Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int. J. Obes. Relat. Metab. Disord. 26, 262-273 (2002).
66. McNeely W, Goa KL. Sibutramine. A review of its contribution to the management of obesity. Drugs 56, 1093-1124 (1998).
67. McNulty SJ, Ur E, Williams G. The Multicenter Sibutramine Study Group. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 26, 125-131 (2003).
68. Hutton B, Fergusson D. Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to hypocaloric diet: a systematic review of randomized clinical trials. Am. J. Clin. Nutr. 80, 1461-1468 (2004).
69. Torgerson JS, Hauptman J, Boldrin MN, Sjostorm L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of diabetes. Diabetes Care 27, 155-161 (2004).
70. Didangelos TP, Thanopoulou AK, Bousboulas SH et al. The ORLIstat and CAcardiovascular risk profile in patients with metabolic syndrome and Type 2 DIAbetes (ORLICARDIA) Study. Curr. Med. Res. Opin. 20, 1393-401 (2004).
71. Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. Diabetes Nutr. Metab. 17, 222-229 (2004).
72. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. JAMA 290, 486-494 (2003).
73. Vijan S, Hayward RA. Pharmacologic lipid-lowering therapy in Type 2 diabetes mellitus: background paper for the American College of Physicians. Ann. Int. Med. 140, 650-658 (2004).
74. Medical Research Council/British Heart Foundation. Heart Protection Study of cholesterol lowering with simvastatin in 29536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360, 7-22 (2002).
75. Buchanan TA, Xiang AH, Peters RK et al. Preservation of pancreatic B-cell function and preservation of Type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51, 2796-2803 (2002).
76. Gaede P, Vedel P, Parving H-H, Pederson O. Intensified multifactorial intervention in patients with Type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomiscd study. Lancet 353, 617-622 (1999).
77. Albu J, Raja-Khan N. The management of the obese diabetic patient. Prim. Care Clin. Office Pract. 30, 465-491 (2003).
78. Toft-Nielsen MB, Madsbad S, Holst JJ. Determinants of the effectiveness of glucagons-like peptide-1 in Type 2 diabetes. J. Clin. Endocrinol. Metab. 86, 3853-3860 (2001).
79. Jones KB. Experience with the Roux-en-Y gastric bypass, and commentary on current trends. Obes. Surg. 10, 183-185 (2000).
80. MacDonald KG, Long SD, Swanson MS et al. The gastric bypass operation reduces the progresson and mortality of non-insulin-dependent diabetes mellitus. J. Gastrointest. Sur. 1, 213-220 (1997).
81. Sjostrom L, Lindroos AK, Peltonen M et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N. Engl. J. Med. 351, 2683-2693 (2004).
82. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Sys Rev. CD004094 (2004).
83. Buchwald H, Avidor Y, Braunwald E et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 292(14), 1724-1737 (2004).
84. Kaufman FR. Type 2 diabetes mellitus in children and youth: a new epidemic. J. Pediatr. Endocrinol. Metab. 15(Suppl. 2), 737-744 (2002).
85. American Diabetes Association. Economic consequences of diabetes mellitus in the US in 1997. Diabetes Care 21, 296-309 (1998).
86. Stockmeyer C, Kuester A, Ramsey D et al. National Nutrition Summit, May 30, 2000: results of the obesity discussion groups. Obes. Res. 9, S41-S52 (2001).
87. Internal Revenue Service. Medical and Dental Expenses. IRS Publication 502. US Government Printing Office, DC, USA (2002).
88. Rothacker DQ. Five-year self-management of weight using meal replacements: comparison with matched controls in rural Wisconsin. Nutrition 16, 344-348 (2000).
89. Ryan DH, Espeland MA, Foster GD et al. Look AHEAD Research Group. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in Type 2 diabetes. Control Clin. Trials 24, 610-628 (2003).
90. Ball SD, Keller KR, Moyer-Mileur LJ, Ding Y-W, Donaldson D, Jackson WD. Prolongation of satiety after low versus moderately high glycemic index meals in obese adolescents. Pediatrics 111, 488-494 (2003).
91. Reynolds LR, Konz EC, Federich RC, Anderson JW. Rosiglitazone amplifies the benefits of lifestyle intervention measures in long-standing Type 2 diabetes mellitus. Diabetes Obes. Metable. 4, 270-275 (2002).
92. Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O'Neil PM. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes. Res. 10, 633-641 (2002).
93. Ashley JM, St. Jeor ST, Perumean-Chaney S, Schrage J, Bovee V. Meal replacements in weight interventions. Obes. Res. 9, 312S-317S (2001).
94. Yip I, Go VLW, DeShields S, Saltsman P et al. Liquid meat replacement and glycemic control in obese Type 2 diabetic patients. Obes. Res. 9, 341S-347S (2001).
95. Mazzone T. Strategies in ongoing clinical trials to reduce cardiovascular disease in patients with diabetes mellitus and insulin resistance. Am. J. Cardiol. 93, 27C-31C (2004).
96. Waitman JA, Aronne LJ. Pharmacotherapy of obesity. Obesity Management 1, 15-19 (2005).